Recombinant human endostatin combined with platinum compounds for malignant pleural effusion: an overview of systematic reviews_West China Medical Journal

Authors：

LI Zeyun ¹ , LAN Qingxia ¹ , LIU Chengxin ¹ ,  CAO Yang ²

1. The First Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510405, P. R. China;
2. Department of Oncology, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510405, P. R. China;

Corresponding?author：

CAO Yang, Email: 393556828@qq.com

Keywords：

Recombinant human endostatin; platinum compounds; malignant pleural effusion; systematic review; overview

DOI：

10.7507/1002-0179.202008254

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To overview the systematic reviews of recombinant human endostatin combined with platinum compounds for malignant pleural effusion (MPE). Methods According to the inclusion and exclusion criteria and searching strategies, we screened the systematic reviews of recombinant human endostatin combined with platinum compounds for the treatment of MPE by searching the Embase, PubMed, Clinical Trials, Cochrane Library, China National Knowledge Infrastructure, CQVIP Database and Wanfang Database. The searching time was from January 1999 to December 2021. The methodological quality was evaluated using AMSTAR 2 tool, the report quality was evaluated using PRISMA statement, and the evidence quality of the outcome indicators was graded according to the GRADE system. Finally, RevMan 5.3 software was used to quantitatively merge and analyze the original research effect values of the main outcome indicators with low level of evidence. Results A total of 9 systematic reviews/meta-analyses involving 8 outcome indicators and totally 50 outcomes were included. The average PRISMA scale score was 22.28±1.37, with 6 reports being relatively complete and 3 reports having certain reporting defects. The overall methodological quality of the 9 systematic reviews was extremely low. Most of the 50 outcomes were graded as “low” (31 outcomes) or “intermediate” (18 outcomes) quality. The results of 9 systematic reviews all showed that the clinical efficacy of dual therapy was more satisfactory than that of platinum-based preparations in the treatment of MPE, and re-quantitative analysis also confirmed that there was no statistically significant difference in the incidence of adverse events between the two treatments (P>0.05). Conclusions Considering the existing evidence and the results of meta-analysis, the dual therapy composed of recombinant human endostatin and platinum compounds is more effective in the treatment of MPE, and there is no difference in the incidence of related adverse events. However, because of its poor methodological quality and the low level of evidence, the above conclusions can only provide a certain reference and need to be confirmed by further research.

Citation： LI Zeyun, LAN Qingxia, LIU Chengxin, CAO Yang. Recombinant human endostatin combined with platinum compounds for malignant pleural effusion: an overview of systematic reviews. West China Medical Journal, 2022, 37(1): 48-55. doi: 10.7507/1002-0179.202008254 Copy

1.	Clive A, Jones H, Bhatnagar R, et al. Interventions for the management of malignant pleural effusions: a network meta-analysis. Cochrane Database Syst Rev, 2016(5): CD010529.
2.	Heffner JE. Management of the patient with a malignant pleural effusion. Semin Respir Crit Care Med, 2010, 31(6): 723-733.
3.	Roberts ME, Neville E, Berrisford RG, et al. Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax, 2010, 65(Suppl 2): ii32-ii40.
4.	Penz E, Watt KN, Hergott CA, et al. Management of malignant pleural effusion: challenges and solutions. Cancer Manag Res, 2017, 9: 229-241.
5.	Moher D, Liberati A, Tetzlaff J, et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. J Clin Epidemiol, 2009, 62(10): 1006-1012.
6.	Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ, 2017, 358: j4008.
7.	Guyatt GH, Oxman AD, Schünemann HJ, et al. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol, 2011, 64(4): 380-382.
8.	Liang R, Xie HY, Lin Y, et al. Intraperitoneal perfusion therapy of endostar combined with platinum chemotherapy for malignant serous effusions: a meta-analysis. Asian Pac J Cancer Prev, 2015, 16(18): 8637-8644.
9.	韓娜娜, 徐細明. 恩度聯合化療藥物灌注治療惡性胸腹腔積液效果的系統評價. 中國醫藥導報, 2015, 12(28): 103-107.
10.	謝海英. 恩度聯合鉑類藥物腔內灌注治療惡性漿膜腔積液隨機對照試驗的 meta 分析. 南寧: 廣西醫科大學, 2015.
11.	Biaoxue R, Xiguang C, Hua L, et al. Thoracic perfusion of recombinant human endostatin (Endostar) combined with chemotherapeutic agents versus chemotherapeutic agents alone for treating malignant pleural effusions: a systematic evaluation and meta-analysis. BMC Cancer, 2016, 16(1): 888.
12.	楊閩潔, 何煒, 王峰, 等. 重組人血管內皮抑制素聯合順鉑胸腔灌注化療治療惡性胸腔積液的 Meta 分析. 臨床腫瘤學雜志, 2015, 20(12): 1117-1123.
13.	蔣俊, 解佳奇, 張麗, 等. 重組人血管內皮抑素聯合順鉑治療惡性胸腔積液的 Meta 分析. 實用癌癥雜志, 2016, 31(3): 411-416.
14.	劉自力, 黃禮年, 王斌, 等. 恩度聯合順鉑治療非小細胞肺癌合并惡性胸腔積液的 Meta 分析. 中國循證醫學雜志, 2016, 16(5): 557-563.
15.	孫園園, 余正. 恩度聯合順鉑治療惡性胸腔積液的 Meta 分析. 現代商貿工業, 2016, 37(33): 166-169.
16.	楊惠萍, 陳婷, 應苗法. 重組人血管內皮抑制素聯合順鉑腔內注射治療惡性胸腔積液療效和安全性的 Meta 分析. 腫瘤學雜志, 2016, 22(5): 410-416.
17.	劉明濤, 閆鵬鵬, 常剛, 等. 胸腔內注入恩度聯合鉑類制劑治療惡性胸腔積液療效及安全性的系統評價. 中國醫師雜志, 2017, 19(2): 257-262.
18.	呂傳峰, 王珊, 袁方, 等. 重組人血管內皮抑素聯合順鉑胸腔灌注治療惡性胸腔積液近期療效的 Meta 分析. 醫藥導報, 2017, 36(5): 558-563.
19.	趙子舒, 楊雁鴻, 王小玉, 等. 重組人血管內皮抑制素聯合順鉑治療非小細胞肺癌惡性胸腔積液的療效及安全性的 Meta 分析. 亞洲腫瘤科病例研究, 2018, 7(3): 17-25.
20.	周燕群, 郭勇, 楊笑奇. 恩度聯合順鉑腔內注射治療肺癌合并惡性胸腔積液 meta 分析. 實用腫瘤雜志, 2018, 33(6): 553-560.
21.	Qureshi NR, Rahman NM, Gleeson FV. Thoracic ultrasound in the diagnosis of malignant pleural effusion. Thorax, 2009, 64(2): 139-143.
22.	Chen Y, Mathy NW, Lu H. The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with non-small cell lung cancer (Review). Mol Med Rep, 2018, 17(6): 8019-8030.
23.	Folkman J. Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res, 2006, 312(5): 594-607.
24.	Zhao WY, Chen DY, Chen JH, et al. Effects of intracavitary administration of Endostar combined with cisplatin in malignant pleural effusion and ascites. Cell Biochem Biophys, 2014, 70(1): 623-628.

1. Clive A, Jones H, Bhatnagar R, et al. Interventions for the management of malignant pleural effusions: a network meta-analysis. Cochrane Database Syst Rev, 2016(5): CD010529.
2. Heffner JE. Management of the patient with a malignant pleural effusion. Semin Respir Crit Care Med, 2010, 31(6): 723-733.
3. Roberts ME, Neville E, Berrisford RG, et al. Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax, 2010, 65(Suppl 2): ii32-ii40.
4. Penz E, Watt KN, Hergott CA, et al. Management of malignant pleural effusion: challenges and solutions. Cancer Manag Res, 2017, 9: 229-241.
5. Moher D, Liberati A, Tetzlaff J, et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. J Clin Epidemiol, 2009, 62(10): 1006-1012.
6. Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ, 2017, 358: j4008.
7. Guyatt GH, Oxman AD, Schünemann HJ, et al. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol, 2011, 64(4): 380-382.
8. Liang R, Xie HY, Lin Y, et al. Intraperitoneal perfusion therapy of endostar combined with platinum chemotherapy for malignant serous effusions: a meta-analysis. Asian Pac J Cancer Prev, 2015, 16(18): 8637-8644.
9. 韓娜娜, 徐細明. 恩度聯合化療藥物灌注治療惡性胸腹腔積液效果的系統評價. 中國醫藥導報, 2015, 12(28): 103-107.
10. 謝海英. 恩度聯合鉑類藥物腔內灌注治療惡性漿膜腔積液隨機對照試驗的 meta 分析. 南寧: 廣西醫科大學, 2015.
11. Biaoxue R, Xiguang C, Hua L, et al. Thoracic perfusion of recombinant human endostatin (Endostar) combined with chemotherapeutic agents versus chemotherapeutic agents alone for treating malignant pleural effusions: a systematic evaluation and meta-analysis. BMC Cancer, 2016, 16(1): 888.
12. 楊閩潔, 何煒, 王峰, 等. 重組人血管內皮抑制素聯合順鉑胸腔灌注化療治療惡性胸腔積液的 Meta 分析. 臨床腫瘤學雜志, 2015, 20(12): 1117-1123.
13. 蔣俊, 解佳奇, 張麗, 等. 重組人血管內皮抑素聯合順鉑治療惡性胸腔積液的 Meta 分析. 實用癌癥雜志, 2016, 31(3): 411-416.
14. 劉自力, 黃禮年, 王斌, 等. 恩度聯合順鉑治療非小細胞肺癌合并惡性胸腔積液的 Meta 分析. 中國循證醫學雜志, 2016, 16(5): 557-563.
15. 孫園園, 余正. 恩度聯合順鉑治療惡性胸腔積液的 Meta 分析. 現代商貿工業, 2016, 37(33): 166-169.
16. 楊惠萍, 陳婷, 應苗法. 重組人血管內皮抑制素聯合順鉑腔內注射治療惡性胸腔積液療效和安全性的 Meta 分析. 腫瘤學雜志, 2016, 22(5): 410-416.
17. 劉明濤, 閆鵬鵬, 常剛, 等. 胸腔內注入恩度聯合鉑類制劑治療惡性胸腔積液療效及安全性的系統評價. 中國醫師雜志, 2017, 19(2): 257-262.
18. 呂傳峰, 王珊, 袁方, 等. 重組人血管內皮抑素聯合順鉑胸腔灌注治療惡性胸腔積液近期療效的 Meta 分析. 醫藥導報, 2017, 36(5): 558-563.
19. 趙子舒, 楊雁鴻, 王小玉, 等. 重組人血管內皮抑制素聯合順鉑治療非小細胞肺癌惡性胸腔積液的療效及安全性的 Meta 分析. 亞洲腫瘤科病例研究, 2018, 7(3): 17-25.
20. 周燕群, 郭勇, 楊笑奇. 恩度聯合順鉑腔內注射治療肺癌合并惡性胸腔積液 meta 分析. 實用腫瘤雜志, 2018, 33(6): 553-560.
21. Qureshi NR, Rahman NM, Gleeson FV. Thoracic ultrasound in the diagnosis of malignant pleural effusion. Thorax, 2009, 64(2): 139-143.
22. Chen Y, Mathy NW, Lu H. The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with non-small cell lung cancer (Review). Mol Med Rep, 2018, 17(6): 8019-8030.
23. Folkman J. Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res, 2006, 312(5): 594-607.
24. Zhao WY, Chen DY, Chen JH, et al. Effects of intracavitary administration of Endostar combined with cisplatin in malignant pleural effusion and ascites. Cell Biochem Biophys, 2014, 70(1): 623-628.

West China Medical Journal

Recombinant human endostatin combined with platinum compounds for malignant pleural effusion: an overview of systematic reviews

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content